InoRx
Simplifying Trials. Accelerating Cures.

InoRx - Your High-Enrolling Clinical Research Partner in India

Designed for high-enrollment studies requiring speed, scale, and predictable execution. Backed by the SRM Group, a $1.4B+ leader in hospital systems and education with a global presence anchored in Chennai.

Proof Points

500,000+ Patients

400+ Sites

800+ Clinicians

15+ Years

Phase 1 Unit (20–50 Beds)

Therapeutic Focus



- Infectious Diseases & Vaccines
- Respiratory & Pulmonary
- Women's & Neonatal Health
- Dermatology

In addition, the scale of the SRM hospital network and a robust external site network enable strong support in:

- **Cardiometabolic**
- **Oncology**
- **Inflammatory & Immune Conditions**

Market Focus

Phase 1	Phase 2-3	Biosimilars & Generics (SMD)	Phase 4 & Registries
First-in-human (1a, 1b), disease-agnostic	Fast, high-volume, patient enrollment across core therapeutic areas	PK/PD, bioequivalence, and registrational programs	Large-scale, compliant follow-up and real-world studies

Why InoRx

- **Faster Study Start and Enrollment**
  Embedded hospital infrastructure enables rapid site activation and patient recruitment
- **High-Enrollment Execution Model**
  Direct access to large pre-existing patient populations supports consistent enrollment
- **Proven in High-Volume Settings**
  15+ years of execution within the SRM hospital network in high-volume clinical environments
- **Quality Without Tradeoffs**
  ICMR-certified environment with established clinical, safety, and regulatory processes

Integrated Site & Patient Access Model

Built within the SRM hospital ecosystem, InoRx integrates:

- **Embedded investigators**
- **Integrated clinical sites**
- **Direct patient access**

Resulting in faster enrollment, stronger retention, and more predictable execution

FACT SHEET: InoRx–Your High-Enrolling Clinical Research Partner in India

Backed by the SRM Group

- InoRx is funded by the SRM Group, a $1.4B+ global leader in hospital systems and medical education. This relationship provides direct access to owned clinical infrastructure, investigators, and patient populations, enabling high-enrollment clinical trial execution at scale.

Demonstrated Experience

- 15+ years of clinical trial execution through the SRM ecosystem
- Experience across Phase I–IV studies, including controlled and real-world settings
- Execution of biosimilar and post-marketing programs
- Consistent performance in high-enrollment, time-sensitive study environments
- Execution in cost-sensitive, large-scale programs aligned to Indian pharma requirements
- Collaboration with global CRO partners, including IQVIA

Clinical Infrastructure & Capacity

- Phase 1 unit with 20 beds operational today
- 30–50 beds available with short-term expansion (1–2 months)
- Integrated hospital infrastructure enabling rapid capacity scaling without external site dependency

Laboratory Capabilities

- Central lab supporting high-volume sample processing
- Bioanalytical capabilities for PK/PD and bioequivalence studies
- Standardized, validated processes for sample handling, storage, and analysis

Service Scope

End-to-end clinical development support includes:

- Trial design and feasibility
- Clinical operations and monitoring
- Data management and analysis
- Regulatory submission support
- Safety and pharmacovigilance

Therapeutic Area Depth

Supported by high-volume patient populations and integrated clinical environments within the SRM network

- Infectious disease and vaccines - High-volume vaccine and infectious disease studies with rapid enrollment in acute care settings
- Respiratory and pulmonary conditions - Asthma, COPD, and infectious respiratory studies supported by strong patient flow and continuity of care
- Women's and neonatal health - Women's health, peri- and post-partum, neonatal, and OB/GYN studies with access to specialized populations
- Cardiometabolic disease, including diabetes and cardiovascular outcomes - Cardiometabolic programs, including diabetes and cardiovascular outcomes studies, supported by large chronic disease populations
- Oncology, including biosimilars - Oncology studies, including biosimilar programs, with access to diverse patient populations and long-term follow-up capability
- Chronic inflammatory and immune-mediated conditions - Chronic inflammatory and immune-mediated disease studies with access to longitudinal patient cohorts

Patient Access & Site Infrastructure

- Large, integrated hospital network with access to 500,000+ patients annually
- 400+ clinical sites across SRM and affiliated network
- 800+ clinicians, including 200+ principal investigators supporting rapid recruitment
- Strong patient retention driven by continuity of care across integrated hospital and affiliated site networks

Clinical & Operational Capabilities

- Phase 1 unit supporting controlled clinical studies
- Bioequivalence and PK/PD study execution
- Clinical operations, monitoring, and site management
- Data management and statistical support
- Regulatory and submission support
- Safety and pharmacovigilance processes

Quality & Systems

- ICMR-certified clinical research environment
- Established Quality Management System (QMS)
- SOP framework supporting clinical and laboratory operations
- Structured safety reporting and monitoring processes
- Audit ready data aligned with global regulatory standards

Designed for Speed and Scale

InoRx combines:

- Integrated site and hospital infrastructure
- High patient volume
- Centralized operational discipline to deliver:
  - Faster study startup
  - Accelerated enrollment
  - High-quality, reliable data

Support for Indian Pharma and Global Sponsors

Support includes:

- Biosimilar development programs
- Generics (SMD) and bioequivalence studies
- Phase II–III registrational trials
- Phase IV and real-world evidence programs

InoRx
Simplifying Trials. Accelerating Cures.

hello@inorx.com
www.inorx.com